Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation.

Dossabhoy NR, McRight S, Sangha B, Khan S, Adgeh C.

J La State Med Soc. 2013 Sep-Oct;165(5):283-5.

PMID:
24350530
2.

An unusual complication of treatment with orlistat.

Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ.

Clin Nephrol. 2009 Apr;71(4):430-2.

PMID:
19356376
3.

Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.

Singh A, Sarkar SR, Gaber LW, Perazella MA.

Am J Kidney Dis. 2007 Jan;49(1):153-7.

PMID:
17185156
4.

Orlistat and calcium oxalate crystalluria: an association that needs consideration.

Ahmed MH.

Ren Fail. 2010;32(8):1019-21. doi: 10.3109/0886022X.2010.501929. Review.

PMID:
20722574
5.

Over-the-counter weight loss with orlistat?

[No authors listed]

Drug Ther Bull. 2009 Nov;47(11):125-7. doi: 10.1136/dtb.2009.10.0046.

PMID:
19887686
6.

Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease.

Buysschaert B, Aydin S, Morelle J, Hermans MP, Jadoul M, Demoulin N.

Diabetes Metab. 2016 Feb;42(1):62-4. doi: 10.1016/j.diabet.2015.08.006. Epub 2015 Oct 9.

PMID:
26454353
7.

Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting.

Schwartz SM, Bansal VP, Hale C, Rossi M, Engle JP.

Obesity (Silver Spring). 2008 Mar;16(3):623-9. doi: 10.1038/oby.2007.96. Epub 2008 Jan 24.

8.

Safety profile of orlistat: results of a prescription-event monitoring study.

Acharya NV, Wilton LV, Shakir SA.

Int J Obes (Lond). 2006 Nov;30(11):1645-52. Epub 2006 Mar 21.

PMID:
16552401
9.

Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria.

Kwan TK, Chadban SJ, McKenzie PR, Saunders JR.

Nephrology (Carlton). 2013 Mar;18(3):241-2. doi: 10.1111/j.1440-1797.2012.01649.x. No abstract available.

PMID:
23432752
10.

Orlistat: hepatitis and oxalate nephropathy.

[No authors listed]

Prescrire Int. 2012 Mar;21(125):71. No abstract available.

PMID:
22428191
11.

[Pharmacological sheet. Orlistat, oral administration (Xenical, Alli). ].

[No authors listed]

J Pharm Belg. 2009 Jun;(2):67-8. Review. French. No abstract available.

PMID:
19739531
12.

Is there a link between calcium oxalate crystalluria, orlistat and acute tubular necrosis?

Karamadoukis L, Ludeman L, Williams AJ.

Nephrol Dial Transplant. 2008 May;23(5):1778-9. doi: 10.1093/ndt/gfm945. Epub 2008 Feb 13. No abstract available.

PMID:
18272781
13.

Orlistat without a prescription: drug interactions, pancreatitis and kidney disorders.

[No authors listed]

Prescrire Int. 2010 Jun;19(107):125. No abstract available.

PMID:
20740721
14.

Orlistat, an under-recognised cause of progressive renal impairment.

Coutinho AK, Glancey GR.

Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv172-4. doi: 10.1093/ndt/gft066. Epub 2013 Sep 18.

PMID:
24049105
15.

Orlistat-induced fulminant hepatic failure.

Sall D, Wang J, Rashkin M, Welch M, Droege C, Schauer D.

Clin Obes. 2014 Dec;4(6):342-7. doi: 10.1111/cob.12075. Epub 2014 Sep 29.

PMID:
25826164
17.

The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.

Perrio MJ, Wilton LV, Shakir SA.

Obesity (Silver Spring). 2007 Nov;15(11):2712-22.

18.

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.

Diabetes Obes Metab. 2005 Nov;7(6):699-708.

PMID:
16219013
19.
20.

Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature.

Barbaro D, Orsini P, Pallini S, Piazza F, Pasquini C.

Endocr Pract. 2002 Mar-Apr;8(2):124-6. Review.

PMID:
11942778

Supplemental Content

Support Center